Peter E. Jensen, M.D.

Bio

Dr. Jensen is Chairman of the Department of Pathology in the School of Medicine and Chairman of the Board of Directors, ARUP Laboratories, University of Utah’s national diagnostic reference laboratory. He received his M.D. from Vanderbilt University, followed by residency training in Anatomic Pathology and research training in immunology at Washington University. Dr. Jensen joined the faculty of the Department of Pathology and Laboratory Medicine at Emory University in 1986, where he ultimately served as Professor, Vice Chair, Director of the Experimental Pathology Division, Medical Director of the Clinical Immunology Laboratory at Emory University Hospital, and Director of the interdepartmental graduate program in Immunology and Molecular Pathogenesis. He has broad interests in health care transformation, precision diagnostics, and the application of new technology in pathology and laboratory medicine. Dr. Jensen joined the University of Utah in 2004.

Board Certification and Academic Information

Board Certification and Academic Information

Academic Office Locations

Academic Bio

Dr. Jensen is Chairman of the Department of Pathology in the School of Medicine and Chairman of the Board of Directors, ARUP Laboratories, University of Utah’s national diagnostic reference laboratory. He received his M.D. from Vanderbilt University, followed by residency training in Anatomic Pathology and research training in immunology at Washington University. Dr. Jensen joined the faculty of the Department of Pathology and Laboratory Medicine at Emory University in 1986, where he ultimately served as Professor, Vice Chair, Director of the Experimental Pathology Division, Medical Director of the Clinical Immunology Laboratory at Emory University Hospital, and Director of the interdepartmental graduate program in Immunology and Molecular Pathogenesis. His research interests are focused on the role of histocompatibility molecules in the immune system, antigen processing and presentation, and the immunology of type 1 diabetes. He joined the University of Utah in 2004.

Education History

Selected Provider Publications

Journal Article

1. LI Q, Shakya A, Guo X, Zhang H, Tantin D, Jensen PE, Chen X (2012). Constitutive nuclear localization of NAT in Foxp3+ regulatory T cells independent of calcineurin activity. J Immunol, 188, 4268-4277.
2. Chen L, Jay Dc, Fairbanks JD, He X, Jensen PE (2011). An MHC class 1b-restricted CD8+T cell response to lymphocytic choriomeningitis virus. J Immunol, 187, 6463-6472.
3. Escobar H, Reyes-Vargas E, Jensen PE, Delgado JC, Crockett, DK (2011). Utility of characteristic QTOF MS/MS fragmentation for MHC class I peptides. J Proteome Res, 10, 2494-2507.
4. Delgado JC, Escobar H, Crockett DK, Reyes-Vargas E, Jensen PE (2009). Identification of naturally processed ligands in the C57BL/6 mouse using large-scale mass spectrometric peptide sequencing and bioinformatics predication. Immunogenetics, 61, 241-246.
5. Zhou Z, Callaway KA, Weber DA, Jensen PE (2009). Cutting edge: HLA-DM functions through a mechanism that does not require specific conserved hydrogen bonds in class II MHC-peptide complexes. J Immunol, 183, 4187-4191.
6. Chen LC, Delgado JC, Jensen PE, Chen X (2009). Direct expansion of human allospecific Fox P3+CD4+ regulatory T cells with allogeneic B cells for therapeutic application. J Immunol, 183, 4094-4102.
7. Delgado JC, Jensen PE (2008). Cat and mouse. Nat Immunol, 9, 829-830.
8. Chen X, Jensen PE (2008). The role of B lymphocytes as antigen-presenting cells. Arch Immunol Ther Exp (Warsz), 56, 77-83.
9. Chen X, Jensen PE (2008). MHC clsss IIantigen presentation and immunological abnormalities due to deficiency of MHC class II and its associated genes. Exp Mol Pathol, 85, 40-44.